Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced multiple posters on peginesatide (formerly known as Hematide™) have been accepted for presentation at the National Kidney Foundation (NKF) 2011 Spring Clinical Meeting taking place April 26-30, 2011 in Las Vegas, Nevada.

“Peginesatide Phase 3 Trial Subjects vs. a Random Sample of United States Hemodialysis Patients.”

Peginesatide is an investigational agent in development by Affymax and Takeda for the treatment of anemia in chronic renal failure patients on dialysis. The companies and investigators will present three posters highlighting Phase 3 data on peginesatide in dialysis patients with anemia related to chronic renal failure, including additional data on the trial subjects in the EMERALD dialysis studies. Details of the poster presentations at NKF follow:

Wednesday, April 27, 2011, 6:00-7:30 p.m.:

• Safety and Efficacy of Peginesatide for Treatment of Anemia in Hemodialysis Patients Previously on Epoetin Alfa or Beta (Besarab, et al.)
• Safety and Efficacy of Peginesatide for Treatment of Anemia in Hemodialysis Patients Previously on Epoetin Alfa (Schiller, et al.) 
• Peginesatide Phase 3 Trial Subjects vs. a Random Sample of United States Hemodialysis Patients (Yang, et al.)